We present the results of a study that assessed the effects on glycaemic control of lixisenatide in comparison to placebo as an add-on treatment to basal insulin with or without sulfonylurea in terms of HbA1c reduction over a period of 24 weeks in Asian patients with type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.